Hutchinson's tissue oxygenation monitor gets EU nod
This article was originally published in Clinica
Hutchinson Technology has launched its InSpectra StO2 spot check (model 300) in Europe, after CE marking the product. It is designed to measure tissue oxygenation levels in patients with circulatory distress in emergency and critical care environments, and consists of a hand-held device and noninvasive sensor employing near infrared spectroscopy that is placed on the thumb. Patients with low levels are at risk of poor clinical outcomes; once identified, they can then be continuously monitored with the firm's InSpectra StO2 tissue oxygenation monitor (model 650) and treated accordingly. The Hutchinson, Minnesota-based firm has also filed a 510(k) application for the StO2 spot check test with the US FDA.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.